about
The Multiple Roles of Microrna-223 in Regulating Bone MetabolismThe roles of bone-derived exosomes and exosomal microRNAs in regulating bone remodellingIdentification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery.Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiencyParacrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing.Blimp1-mediated repression of negative regulators is required for osteoclast differentiation.Transcriptional regulation of bone and joint remodeling by NFATConcise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration.Critical role of MKP-1 in lipopolysaccharide-induced osteoclast formation through CXCL1 and CXCL2.Exogenous IFN-beta regulates the RANKL-c-Fos-IFN-beta signaling pathway in the collagen antibody-induced arthritis model.The effects of diode laser (660 nm) on the rate of tooth movements: an animal study.Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.RNA therapeutics targeting osteoclast-mediated excessive bone resorption.Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation.Denosumab in postmenopausal osteoporosis: what the clinician needs to know.Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.TRAP-positive osteoclast precursors mediate ROS/NO-dependent bactericidal activity via TLR4A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis.Myeloid lineage skewing due to exacerbated NF-κB signaling facilitates osteopenia in Scurfy mice.The peripheral cannabinoid receptor knockout mice: an update.Increased lymphangiogenesis in joints of mice with inflammatory arthritisAnti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) modelOsteoclast fusion and regulation by RANKL-dependent and independent factors.RANK ligand inhibition with denosumab for the management of osteoporosis.Functions of RANKL/RANK/OPG in bone modeling and remodeling.Temporal differential effects of proinflammatory cytokines on osteoclastogenesisThe roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis.The proliferative human monocyte subpopulation contains osteoclast precursors.Denosumab: an investigational drug for the management of postmenopausal osteoporosisNF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism.Osteoclasts have multiple roles in bone in addition to bone resorption.Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.Denosumab--an emerging treatment for postmenopausal osteoporosis.Maintaining the Phenotype Stability of Chondrocytes Derived from MSCs by C-Type Natriuretic Peptide.Quantitative proteomics and integrative network analysis identified novel genes and pathways related to osteoporosis.Lymphangiogenesis, myeloid cells and inflammation.Denosumab for the treatment of osteoporosis and cancer-related conditions.Bone and the innate immune system.Circulating monocytes: an appropriate model for bone-related study.
P2860
Q26778021-74B7671B-2BCE-468D-A1B5-EDDC710AAC3CQ28073668-88242C85-6B41-47A5-BD40-E0E591BFD67EQ30538833-4873F963-D044-4247-B419-1D3AE94CD503Q30912751-E79D6E13-2E0C-4135-A050-53B977B219BDQ33326623-6121E74D-152F-4B6C-B39F-041C46C4D05BQ33733731-1CF4B932-D887-4065-A4B6-9EB244E06A9CQ33998768-1B054DB1-5051-4953-9D50-F5425AE1965EQ34243010-E6EE1825-7E74-4DAF-B6CE-BC96C65385F7Q34622694-28202F3E-CC07-4785-9A40-7332150F34A0Q34751981-5B73BE72-3F78-4767-A2F2-97094179C6EDQ34896715-E5FE1909-620C-428B-908D-D7CC16EB1C0AQ35067806-B550B2F8-3AC7-490B-9FE1-301C6D0EABBBQ35661163-0BA5A9D4-8F73-4E16-8742-7F8AEB30791AQ35800463-E512223E-14D3-494A-A732-AD793CF46B44Q35955440-9D97FBD9-4442-45B1-B37E-5C4332919058Q36056922-5C055E8F-B493-499B-8375-8BC9A9B9F86AQ36058895-C9140E95-5664-4A35-B000-9C21C35A0616Q36061655-E07080FD-7FEB-4926-9DFC-4AF9C9383B1DQ36099992-BE63BF21-3AA2-49A2-99B2-03C08F22B11EQ36293309-6E4328A4-D00F-407B-9687-7AF522BE3C64Q36416347-71DEC99C-E2CE-42E1-B76D-E9AA7538C268Q36465469-10C831A7-82E8-47D1-932D-3AC04019A0F3Q36493751-9BDD5A2D-F464-4F7F-900D-A89340D34BCEQ36568536-FA7FD9D9-DD8B-4684-805A-7F85F2EDFC69Q36600255-C48060AC-5F33-481C-B6DF-6B6E6EE04713Q36700779-B53D78F6-5572-474A-9129-2E84C1F9ABF7Q36753683-E89F1009-DC3C-4096-8FCF-5F90103815D0Q36955377-FC94C8BB-744D-4922-AB12-854EF22F51A8Q37207110-DAE9A74A-1E37-42A7-90CF-A0A80FB325EAQ37307805-D93D267C-73E0-4137-B750-0224A442DC1BQ37363042-993D2147-CBD5-48EB-BFB2-698D1F3EF2B3Q37626090-297408F8-5A31-4D1C-B14F-1FAB18B92116Q37668114-3FF02DE6-2F46-47DE-AF83-B8CFE183EAC3Q37679921-1F404289-9F34-4CCB-ACB9-8A350F9A6384Q37685385-3CB8A533-1BD4-48FB-993F-ECB31EE50CFBQ37716325-660D7A71-0053-4A8B-9FBF-A9583CD3CB92Q37754580-A18014D8-E2AF-4063-BE5D-A7573504DAE1Q37967111-699AEAEF-64A1-46C9-9D7C-79B948594325Q38185586-61010F57-28B8-410E-A6F9-545E46EFF8CCQ38551006-4D2A2DE8-4990-416E-9615-59716969CF0E
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Osteoclast precursors, RANKL/RANK, and immunology.
@ast
Osteoclast precursors, RANKL/RANK, and immunology.
@en
type
label
Osteoclast precursors, RANKL/RANK, and immunology.
@ast
Osteoclast precursors, RANKL/RANK, and immunology.
@en
prefLabel
Osteoclast precursors, RANKL/RANK, and immunology.
@ast
Osteoclast precursors, RANKL/RANK, and immunology.
@en
P2093
P2860
P1476
Osteoclast precursors, RANKL/RANK, and immunology.
@en
P2093
Brendan F Boyce
Edward M Schwarz
Lianping Xing
P2860
P356
10.1111/J.0105-2896.2005.00336.X
P577
2005-12-01T00:00:00Z